Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Bersacapavir in Renal Impairment
NCT04474210Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bersacapavir in Chronic Hepatitis B (CHB) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration, Time to Reach Maximum Observed Plasma Analyte Concentration and 7 more. Started Aug 2020; status: terminated.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04474210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474210.